CIBC analyst Kevin Chiang downgrades NFI Group (TSX:NFI) from Neutral to Underperformer and announces C$8.5 price target.
Relmada Therapeutics Announces Completion Of Treatment In Company’s Registrational Phase 3 RELIANCE III Trial For Rel-1017 As A Monotherapy For Major Depressive Disorder
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completion of patient treatment in RELIANCE III, a monotherapy
